MGS says Auto-injector Reimagined drug-delivery device, which harnesses its design and moldmaking capabilities, can help bring medicines to market faster.

Stevanato Group (NYSE:STVN) executives said the company closed fiscal 2025 with “solid” results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagn ...